Plain language summary: how safe and effective isavuconazole is for treating serious fungal infections in children with weakened immune systems

This Plain Language Summary of Publication article (PLSP) from Expert Review of Anti-Infective Therapy discusses research on isavuconazole, an antifungal medication given orally or intravenously, for treating serious fungal infections (invasive aspergillosis and mucormycosis) in children aged 1-18 years with weakened immune systems. While already approved for both adults and children in the US and Europe, this study aims to expand understanding of isavuconazole’s effectiveness, safety, and optimal dosing specifically in pediatric patients, as current knowledge is primarily based on adult treatment data. The research is important because children with compromised immunity face higher infection risks.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial’ and was published in Antimicrobial Agents and Chemotherapy. 

Visit ASM Journals using the link to read the original article.

• immunocompromised
• invasive aspergillosis
• invasive fungal disease
• isavuconazole
• mucormycosis
• paediatric
• plain language summary
• triazole